Last $4.05 USD
Change Today -0.07 / -1.70%
Volume 311.6K
CERS On Other Exchanges
Symbol
Exchange
CERS is not on other exchanges.
As of 12:55 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

cerus corp (CERS) Snapshot

Open
$4.14
Previous Close
$4.12
Day High
$4.16
Day Low
$4.02
52 Week High
02/25/14 - $8.00
52 Week Low
07/28/14 - $3.48
Market Cap
299.9M
Average Volume 10 Days
1.3M
EPS TTM
$-0.51
Shares Outstanding
74.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CERUS CORP (CERS)

cerus corp (CERS) Related Bloomberg News

View More Bloomberg News

cerus corp (CERS) Related Businessweek News

No Related Businessweek News Found

cerus corp (CERS) Details

Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company in Europe, the Commonwealth of Independent States, and the Middle East. The company develops and commercializes the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and designed to target and inactivate blood-borne pathogens, including viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company’s INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion; and INTERCEPT Blood System for red blood cells is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. Cerus Corporation markets its platelet and plasma systems through its direct sales force and distributors. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

115 Employees
Last Reported Date: 03/7/14
Founded in 1991

cerus corp (CERS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $495.8K
Co-Founder, Chief Medical Officer, Chief Scie...
Total Annual Compensation: $398.2K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $277.0K
President of Cerus Europe and EEMEA
Total Annual Compensation: $304.4K
Senior Vice President of Regulatory Affairs, ...
Total Annual Compensation: $315.4K
Compensation as of Fiscal Year 2013.

cerus corp (CERS) Key Developments

U.S. FDA Accepts IDE Submission by Cerus Making the INTERCEPT Blood System Available to Address Chikungunya and Dengue Blood Safety Risks

Cerus Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted Cerus' clinical protocol to make the INTERCEPT Blood System for platelets available under an Expanded Access Investigational Device Exemption (IDE) to regions in the United States with outbreaks of Chikungunya and dengue virus. Dengue virus is endemic to the Caribbean region. Local transmission of Chikungunya virus was detected in the Caribbean for the first time in February of 2014. Both viruses are spread by species of mosquitoes common in tropical climates as well as regions within the continental U.S. Chikungunya virus causes high fevers, joint pain and swelling, headaches and a rash. Symptoms have been reported to persist for up to 2 years in chronic cases. Rarely, Chikungunya can be fatal. Symptoms of dengue include high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue infection is life threatening due to dengue hemorrhagic fever, which causes bleeding from the nose, gums, or under the skin. It can result in cause dengue shock syndrome, with massive bleeding. As of September 30, 2014, the Centers for Disease Control and Prevention (CDC) has reported 11 confirmed locally transmitted cases of Chikungunya in Florida, 421 cases in Puerto Rico and 45 cases in the U.S. Virgin Islands. Local transmission of dengue has also been reported in Texas and Florida.

Cerus Corporation Submits IDE Supplement to Make Intercept Platelets Available Pre-Approval in U.S. Areas At Risk from Outbreaks of Chikungunya and Dengue

Cerus Corporation announced that it has submitted a clinical protocol to the U.S. Food and Drug Administration (FDA) to make the INTERCEPT Blood System for platelets available under an Expanded Access Investigational Device Exemption (IDE) to regions in the United States with outbreaks of Chikungunya and dengue. The Treatment Use provision allows the FDA to grant early access to a medical treatment not yet approved in the US when no satisfactory alternative is available to treat patients with serious or life-threatening conditions. The protocol submitted by Cerus is designed to allow blood banks and hospitals in geographies threatened by transfusion-transmitted Chikungunya and dengue the earliest possible access to the INTERCEPT treatment of platelet components. The INTERCEPT platelet system license application is under FDA review, with an approval decision expected in 2015. The INTERCEPT system has been approved for use in Europe for 12 years and is used in over 100 blood centers outside the US. In Puerto Rico, there have been approximately 1,000 confirmed cases of Chikungunya infection. The local Department of Health recently issued an administrative order requiring that all blood donations be quarantined for 72 hours pending follow-up on donor history for acute infectious symptoms. Failure to obtain follow-up or a history of symptoms requires the destruction of the donated blood components because there is no approved test available to detect Chikungunya or dengue.

Cerus Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Cerus Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total revenue was $3.849 million against $4.403 million a year ago. Loss from operation was $11.004 million against $7.108 million a year ago. Loss from operations before income taxes was $7.545 million against $6.670 million a year ago. Net loss was $7.589 million or $0.16 per dilute share against $6.724 million or $0.10 per dilute share a year ago. For the six months, total revenue was $7.558 million against $9.046 million a year ago. Loss from operation was $20.223 million against $12.068 million a year ago. Loss from operations before income taxes was $7.732 million against $16.871 million a year ago. Net loss was $7.814 million or $0.28 per dilute share against $16.976 million or $0.26 per dilute share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CERS:US $4.05 USD -0.07

CERS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.01 USD -0.005
Biolase Inc $2.35 USD -0.009
Pluristem Therapeutics Inc $2.91 USD -0.03
STAAR Surgical Co $10.48 USD 0.00
SurModics Inc $20.66 USD -0.03
View Industry Companies
 

Industry Analysis

CERS

Industry Average

Valuation CERS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.3x
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CERUS CORP, please visit www.cerus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.